Theralase Technologies Inc. V.TLT

Alternate Symbol(s): V.TLT.WT | TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc.

Bullboard Posts

Comment by Rayzzeron Sep 22, 2017 2:08am

237 Views

Post# 26729320

RE:180-days cystoscopy of low-dose patient #1 = Sept. 26

Patient #1 may have already had the 180 day follow-up completed on Sept 19th or could have to wait until Oct 3rd at the latest.

The Overall Study Design presented on Page 8 of the Q3 2017 Investor Presentation shows that the 180 day follow-up is plus or minus 7 days.

So, all the dates listed by Bencro could move up a week or be a week later. That includes the 90 day follow-up for Patient #4 as well.

Bullboard Posts

This junior mining stock offers billions in market exposure